Status:
RECRUITING
Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
Lead Sponsor:
RenJi Hospital
Conditions:
High-grade Glioma
Eligibility:
All Genders
18-70 years
Brief Summary
1. To retrospectively explore the feasibility of multi-dimensional heterogeneity imaging features of MRI in predicting the status of key gene mutations in high-grade gliomas; 2. To prospectively explo...
Detailed Description
Glioblastoma, the most prevalent primary intracranial tumor, is characterized by its formidable therapeutic resistance, primarily attributed to its intrinsic heterogeneity. This heightened heterogenei...
Eligibility Criteria
Inclusion
- Retrospective Study:
- Participants aged 18 to 70 years, of any gender.
- Confirmed postoperative pathology of adult diffuse glioma (WHO Grade III-IV).
- Standard MR contrast-enhanced imaging performed within 10 days before surgery.
- No history of prior radiotherapy or chemotherapy before surgery.
- Absence of concurrent significant comorbidities or other tumors.
- Presence of molecular testing results (including IDH, MGMT, 1p19q, TERT, CDKN2A/B, BRAF).
- Availability of comprehensive clinical and follow-up data.
- Prospective Study:
- Participants aged 18 to 70 years, of any gender.
- Clinically suspected to have high-grade gliomas preoperatively, with final pathology confirming high-grade gliomas.
- Stable vital signs and capable of cooperating for a 40-minute MR scan.
- Absence of significant underlying medical conditions or history of other tumors.
- Documentation of informed consent through a signed consent form.
Exclusion
- Retrospective Study:
- MRI images with artifacts or presence of intratumoral hemorrhage.
- Incomplete clinical data available.
- Prospective Study:
- Individuals with claustrophobia or other reasons unable to undergo MRI scans.
- History of allergic reactions to MRI contrast agents.
- Inappropriate for prolonged MRI scans due to other reasons.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06002711
Start Date
September 1 2023
End Date
December 31 2027
Last Update
August 8 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiology, Renji Hospital School of Medicine, Shanghai Jiao Tong University
Shanghai, Select A State Or Province, China, 200127
2
Department of Radiology, Renji hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China, 200127